Liver artery treatment for certain liver cancer patients
Part of Cancer, Digestive system clinical trials.
This early-phase study tests a treatment delivered through the liver’s artery for people with intermediate or limited advanced liver cancer who can’t have surgery. It aims to control the cancer after prior targeted liver treatments didn’t work or the cancer grew again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and have liver cancer confirmed by biopsy or by CT/MRI pattern of specific blood flow in the tumor
- Your cancer stage fits an intermediate stage B or limited stage C situation, and you’ve been offered system (whole-body) treatment but chose not to receive it for stage C
- Your cancer either didn’t respond to prior liver-focused treatments (like chemoembolization, Y90, ablation, or radiation) or grew after them, or it didn’t respond to system therapy
- You can’t be cured with surgery, liver transplant, or targeted freezing/ablation of the tumor
- Your overall condition is fairly strong (ECOG 0–1) and key blood tests and liver function meet study limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.